Figure 5
Figure 5. Hemoglobin increases by PHI. (A) Hemoglobin (g/dL) values are presented with respect to number of days on treatment in 1 rhesus macaque treated with FG-2216 (●) and 1 control animal (○). (B) Hemoglobin levels in treated and control rhesus macaques. In each animal, 2 to 3 hemoglobin values from the last 2 weeks of the treatment period were averaged. The mean hemoglobin values (g/dL) and standard errors shown are derived from all animals in the same treatment cohort. The number of animals for the respective cohorts is as follows: no drug control (n = 2), 40 mg/kg (n = 3; *P = .01), 60 mg/kg (n = 4, **P < .001), and 60 mg/kg with phlebotomy (n = 4, **P < .001).

Hemoglobin increases by PHI. (A) Hemoglobin (g/dL) values are presented with respect to number of days on treatment in 1 rhesus macaque treated with FG-2216 (●) and 1 control animal (○). (B) Hemoglobin levels in treated and control rhesus macaques. In each animal, 2 to 3 hemoglobin values from the last 2 weeks of the treatment period were averaged. The mean hemoglobin values (g/dL) and standard errors shown are derived from all animals in the same treatment cohort. The number of animals for the respective cohorts is as follows: no drug control (n = 2), 40 mg/kg (n = 3; *P = .01), 60 mg/kg (n = 4, **P < .001), and 60 mg/kg with phlebotomy (n = 4, **P < .001).

Close Modal

or Create an Account

Close Modal
Close Modal